Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2010 (2010), Article ID 517198, 8 pages
Research Article

Immunogenicity of Three Different Influenza Vaccines against Homologous and Heterologous Strains in Nursing Home Elderly Residents

1Department of Environmental Medicine and Public Health, Institute of Hygiene, University of Padua, Via loredan 18, 35151 Padua, Italy
2Global Clinical Research and Development, Novartis Vaccines & Diagnostics S.r.l., Via Fiorentina 1, 53100 Siena, Italy
3Local Health Unit n.13, Veneto Region, Via L. Mariutto, 76-30035 Mirano, Italy
4Department of Medicine and Public Health, Section of Hygiene and Preventive, Environmental and Occupational Medicine, University of Verona, Strada Le Grazie, 8-37134 Verona, Italy
5Department of Surgical and Gastroenterological Sciences, University of Padua, Via Giustiniani 2, 35100 Padua, Italy

Received 25 August 2009; Accepted 7 January 2010

Academic Editor: Jiri Mestecky

Copyright © 2010 Vincenzo Baldo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


We studied whether MF59-adjuvanted influenza vaccine improves immunity against drifted influenza strains in institutionalised elderly with underling chronic health conditions. Sera from a randomized study, comparing MF59-adjuvanted (Sub/MF59, ), virosomal (SVV, ), and split ( ) vaccines, were retested using a hemagglutination inhibition (HI) assay against homologous (Northern Hemisphere [NH] 1998/99) and drifted (NH 2006/07) strains. Corrected postvaccination HI antibody titres were significantly higher with Sub/MF59 than SVV for all strains; GMTs against homologous A/H3N2 and B and both drifted A strains were significantly higher for Sub/MF59 than split. Seroprotection rates and mean-fold titer increases were generally higher with Sub/MF59 for all A influenza strains. MF59-adjuvanted influenza vaccine induced greater and broader immune responses in elderly people with chronic conditions, than conventional virosomal and split vaccines, particularly for A/H1 and A/H3 strains, potentially giving clinical benefit in seasons where antigenic mismatch occurs.